Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03784898 · ClinicalTrials.gov registry record · Phase 4
Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada
A Phase 4 study of Multiple Sclerosis, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT03784898 is a Phase 4 study of Multiple Sclerosis that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 13 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03784898, a Phase 4 study of Multiple Sclerosis, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
Primary Objective: To collect blood samples in a new cohort of Relapsing Forms of Multiple Sclerosis (RMS) participants who had developed immune thrombocytopenic purpura (ITP) after LEMTRADA treatment, for future Deoxyribonucleic acid (DNA) analysis as part of a global biomarker project assessing pre-identified candidate single nucleotide polymorphisms (SNPs) associated to the development of ITP after LEMTRADA treatment in RMS participants.
Conditions Studied
Interventions
- OTHER Blood draw for future biomarker analysis
Study Locations (1)
California
- Investigational Site Number 8400001 - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2019-02-08 |
| Est. Completion | 2019-12-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03784898
The ClinicalTrials.gov registry entry for NCT03784898 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (98% lower). The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Blood draw for future biomarker analysis is the first listed.
NCT03784898 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03784898 about?
NCT03784898 is a clinical study titled "Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada". Primary Objective: To collect blood samples in a new cohort of Relapsing Forms of Multiple Sclerosis (RMS) participants who had developed immune thrombocytopenic purpura (ITP) after LEMTRADA treatment, for future Deoxyribonucleic acid (DNA) analysis as part of a global biomarker project assessing p...
What is the current status of trial NCT03784898?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 13 participants. The study started on 2019-02-08. Estimated completion is 2019-12-11.
What conditions does trial NCT03784898 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT03784898?
The interventions under investigation include: Blood draw for future biomarker analysis (OTHER).
Who is sponsoring clinical trial NCT03784898?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03784898 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis
RECRUITING · Phase 4
-
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
RECRUITING · Phase 4
-
Glucose Consumption in MS Using [F-18]FDG-PET
RECRUITING · Phase 4
-
Home Based Infusions for Ocrelizumab
RECRUITING · Phase 4
-
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
RECRUITING · Phase 4
-
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.